The role of taxanes in the treatment of breast cancer

Bibliography

• GREENLEE RT, HILL-HARMON MB, MURRAY Y et al.: Cancer statistics, 2001.. A. Cancer J. Clin. (2001) 51:15–36.
   Google Scholar
• ELLIS MJ, HAYES DF, LIPPMAN ME: Treatment of metastatic breast cancer. In Breast Diseases (3rd Edition). JR Harris, ME Lippman, M Morrow, CK Osborne (Eds), Lippincott, Philadelphia, PA, USA (2004) 1101–1159.
   Google Scholar
• CROWN J: Evolution in the treatment of advanced breast cancer. Semin. Oncol (1998) 25( suppl 12): 12–17.
   Google Scholar
• BULL JM, TORMEY DC, LI SH et al.: A randomized comparative trial of Adriamycin versus methotrexate in combination chemotherapy. Cancer (1978) 41:1649–1657.
   PubMed Web of Science ®Google Scholar
• CUMMINGS FJ, GELMAN R, HORTON Jet al.: Comparison of CAF versus CMFP in metastatic breast cancer: Analysis of prognostic factors.. Oncol (1985) 3:932–940.
   Google Scholar
• AISNER J, WEINBERG V, PERLOFF M et al.: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER for metastatic carcinoma of the breast: A CALGB study.. Oncol (1987) 5:1523–1533.
   Google Scholar
• FALKSON G, TORMEY DC, CAREY P et al.: Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer. Eur. J. Cancer (1991) 27:973–977.
   PubMedGoogle Scholar
• FOSSATI R, CONFALONIERRI C, TORRI Vet al.: Cytotoxic and hormonal for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.. Oncol. (1998) 16:3439–3460.
   Google Scholar
• GREENBERG PA, HORTOBAGYI GN,SMITH TL et al.: Long term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol (1996) 14:2197–2205.
   Google Scholar
• JOENSUU H, HOLLI K, M et al.: Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J. Clin. Oncol (1998) 16:3720–3730.
   PubMed Web of Science ®Google Scholar
• LEVINE MN, BRAMWELL VT-I, PRITCHARD KI et al.: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J. Clin. Oncol (1998) 16:2651–2658.
   PubMedGoogle Scholar
• COOMBES RC, BLISS JM, WILS Jet al.: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial.. Oncol (1996) 14:35–45.
   Google Scholar
• BONADONNA G, ZAMBETTI M, VALAGUSSA P: Doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil for breast cancer (letter). JAMA (1995) 274:796–797.
   PubMedGoogle Scholar
• MISSET JL, DI PALMA M, M et al.: Adjuvant treatment node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J. Clin. Oncol (1996) 14:1136–1145.
   PubMed Web of Science ®Google Scholar
• CARPENTER JT, VELEZ-GARCIA E, ARON BS et al.: Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (adriamycin) and fluorouracil (CAF) versus cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast cancer. Proc. Am. Soc. Clin. Oncol1994) 13:68a.
   Google Scholar
• EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet (1998) 352:930–942.
   PubMed Web of Science ®Google Scholar
• WANI MC, TAYLOR HL, WALL ME, COGGON P, MCPHAIL AT: Plant antitumour agents VI. The isolation and structure of taxol, a novel antileukemic and antitumour agent from Taxus brevifilia. J. Am. Chem. Soc. (1971) 93:2325–2327.
   Google Scholar
• ROWINSKY EK, DONEHOWER RC: Drug therapy: paclitaxel (Taxol). Engl. J. Med. (1995) 332:1004–1014.
   PubMed Web of Science ®Google Scholar
• •Review of the early development of paclitaxel.
   Google Scholar
• LAVELLE F, GUERITTE-VOEGELEIN F, GUENARD D: Le taxotere: des aiguilles d'if a la clinique. Bull Cancer (1993) 80:326–338.
   PubMedGoogle Scholar
• GLIGOROV J, LOTZ JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist (2004) 9 (Suppl. 2):3–8.
   Google Scholar
• LEGHA SS, TENNEY DM, IR: Phase I study of taxol using 5 day intermittent schedule.. Oncol (1986) 4:762–766.
   Google Scholar
• DONEHOWER RC, ROWINSKY EK, GROCHOW LB et al.: Phase I trial of Taxol in patients with advanced cancer. Cancer Treat. Rep. (1987) 71:1171–1177.
   PubMedGoogle Scholar
• WIERNIK PH, SCHWARTZ EL, STRAUMAN JJ et al.: Phase I clinical and pharmacokinetic study of Taxol. Cancer Res. (1987) 47:2486–2493.
   PubMed Web of Science ®Google Scholar
• SCHILLER JH, STORER B, TUTSCH K et al.: Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J. Clin. Oncol. (1994) 12:241–248.
   PubMed Web of Science ®Google Scholar
• BROWN T, HALVIN K, WEISS G et al: A Phase I trial of Taxol given by a 6-hour intravenous infusion. J. Clin. Oncol. (1991) 9:1261–1267.
   PubMed Web of Science ®Google Scholar
• WIERNIK PH, SCHWARTZ EL, EINZIG A et al.: Phase I trial of Taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J. Clin. Oncol. (1987) 5:1232–1239.
   PubMed Web of Science ®Google Scholar
• HURWITZ CA, RELLING MV, SD et al.: Phase I trial of paclitaxel in children with refractory solid tumors: A Pediatric Oncology Group study. J. Clin. Oncol. (1993) 11:2324–2329.
   PubMedGoogle Scholar
• ROWINSKY EK, BURKE PJ, KARP JE et al.: Phase I and pharmacodynamic study of Taxol in refractory adult acute leukemias. Cancer Res. (1989) 49:4640–4647.
   PubMed Web of Science ®Google Scholar
• SAROSY G, KOHN E, STONE DA et al:Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J. Clin. Oncol (1992) 10:1165–1170.
   PubMed Web of Science ®Google Scholar
• WILSON WH, BERG S, BRYANT G et al.: Paclitaxel in doxorubicin-refractory or mitomycin-refractory breast cancer: A Phase I/II trial with 96-hour infusion.. Oncol (1994) 12:1621–1629.
   Google Scholar
• SPRIGGS DR, TONDINI C: Taxol administered as a 120 hour infusion. Invest. New Drugs (1992) 10:275–278.
   PubMed Web of Science ®Google Scholar
• WEISS RB, DONEHOWER RC, PH et al.: Hypersensitivity reactions from Taxol. j Clin. Oncol. (1990) 12:1263–1268.
   Google Scholar
• EXTRA JM, ROUSSEAU F, BRUNO R al.: Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as short intravenous infusion. Cancer Res.1993) 53: 1037–1042.
   Google Scholar
• BURRIS H, IRVIN R, KUHN J et al: Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J. Clin. Oncol (1993) 11:950–958.
   PubMed Web of Science ®Google Scholar
• BISSETT D, SETANOIANS A, CASSIDY J et al.: Phase land pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res. (1993) 53:523–527.
   PubMed Web of Science ®Google Scholar
• PAZDUR R, NEWMAN RA, NEWMAN BM et al.: Phase I study of Taxotere: Five-day schedule. J. Natl. Cancer Inst. (1992) 84:1781–1788.
   PubMed Web of Science ®Google Scholar
• TOMIAK E, PICCART MJ, KERGER J et al.: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J. Clin. Oncol (1994) 12:1458–1467.
   PubMed Web of Science ®Google Scholar
• TAGUCHI T, FURUE H, NIITANI H et al.: Phase I clinical trial of RP 56976 (docetaxel), a new anticancer drug. Gan To Kagaku Ryoho (1994) 21: 1997-2005.
   Google Scholar
• TRUDEAU ME: Docetaxel (taxotere): an overview of first-line monotherapy. Semin. Oncol. (1995) 22 (suppl 13):17–21.
   Google Scholar
• NABHOLTZ JM, TONKIN K, M et al.: Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Expert Opin. Pharmacother. (2000) 1:187–206.
   Google Scholar
• SEIDMAN AD, HUDIS CA, ALBANEL Jet al.: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol (1998) 16:3353–3361.
   Google Scholar
• PEREZ EA, VOGEL CL, IRWIN DH et al.: Multicenter Phase II trial of weekly paclitaxel in women with metastatic breast cancer. J. Clin. Oncol. (2001) 19:4216–4223.
   PubMed Web of Science ®Google Scholar
• GREEN MC, BUZDAR AU, SMITH T et al.: Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q3 wk) P therapy (tx) followed by FAC-final results of a prospective Phase III randomized trial. Proc. Am. Soc. Clin. Oncol. (2002) 21:35a.
   Google Scholar
• GIANNI L, VIGANO L, LOCATELLI A et al.: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and in patients with breast cancer.Clin. Oncol. (1997) 15: 1906-1915.
   Google Scholar
• • Paclitaxel and doxorubicin combination: Phase II trials and pharmacokinetics/ advanced breast cancer.
   Google Scholar
• GEHL J, BOESGAARD M, PAASKET T al.: Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann. Oncol (1996) 7:687–693.
   Google Scholar
• • Paclitaxel and doxorubicin combination: II trials and pharmacokinetics/ advanced breast cancer.
   Google Scholar
• GIANNI L, MUNZONE E, CAPRI G et al.: Paclitaxel by 3-hour infusion in combination with bolus doxorubicine in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-sequence-finding study.. Oncol. (1995) 13:2688–2699.
   Google Scholar
• • Paclitaxel and doxorubicin combination: Phase II trials and pharmacokinetics/ advanced breast cancer.
   Google Scholar
• LOFFLER TM: Is there a place for 'dose-dense' weekly schedules of the taxoids? Semin. Oncol (1998) 25 (Suppl. 12):32–34.
   Google Scholar
• MISSET JL, DIERAS V, GRUIA G et al.: Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann. Oncol (1999) 10:553–560.
   PubMed Web of Science ®Google Scholar
• •Docetaxel and doxorubicin combination: Phase II/advanced breast cancer.
   Google Scholar
• NABHOLTZ JM, MACKEY JR, M et al.: Phase II Study of docetaxel,doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.. Oncol. (2001) 19(2): 314–321.
   Google Scholar
• •Docetaxel and doxorubicin combination: Phase II/advanced breast cancer.
   Google Scholar
• SPARANO JA, O'NEILL A, PL et al.: Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.. Oncol (2000) 18:2369–2377.
   Google Scholar
• •Docetaxel and doxorubicin combination: Phase II/advanced breast cancer.
   Google Scholar
• NABHOLTZ JM: Docetaxel (taxotere) plusdoxorubicin-based combinations: the evidence of activity in breast cancer. Semin. Oncol (1999) 26 (Suppl. 9): 7–13.
   Google Scholar
• RUDER Mk SPARREBOOM A, GARRETT-MAYER ES et al.: Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based Eur. J. Cancer (2004) 40:1170–1178.
   Google Scholar
• HOLMES FA, WALTERS RS, THERIAULT RL et al.: Phase II trial of taxol an active drug in the treatment of metastatic breast cancer. J. NatL. Inst. (1991) 83:1797–1805.
   PubMed Web of Science ®Google Scholar
• NABHOLTZ J-M, GELMON K, BONTENBAL M et al.: Multicenter, randomized comparative study of two doses of paclitaxel in patients with Metastatic breast cancer. J. Clin. Oncol. (1996) 14:1858–1867.
   PubMedGoogle Scholar
• ••Registration trial of paclitaxel/advancedbreast cancer.
   Google Scholar
• PERETZ T, SULKES A, CHOLLET P et al.: A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC). Eur. J. Cancer (1995) 31 (Suppl. 5):575a.
   Google Scholar
• •Randomised trials assessing doses and schedules of paclitaxel/advanced breast cancer.
   Google Scholar
• WINER EP, BERRY DA, WOOLF Set al.: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.1 Clin. Oncol. (2004) 22:2061–2068.
   Google Scholar
• ••Randomised trials assessing doses andschedules of paclitaxel/advanced breast cancer.
   Google Scholar
• SMITH RE, BROWN AM, EP et al.: Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J. Clin. Oncol. (1999) 17:3403–3411.
   PubMed Web of Science ®Google Scholar
• ••Randomised trials assessing doses andschedules of paclitaxel/advanced breast cancer.
   Google Scholar
• HOLMES FA, VALERO V BUZDAR AU et al.: Final results: Randomized Phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patient (pt) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (1998) 17:110a.
   Google Scholar
• •Randomised trials assessing doses and schedules of paclitaxel/advanced breast cancer.
   Google Scholar
• CITRON ML, BERRY DA, C et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.. Oncol. (2003) 21:1431-1439. Paclitaxel second-generation adjuvant Phase III trial.
   Google Scholar
• SEIDMAN AD, BERRY D, CIRRINCIONE C et aL: CALGB 9840:Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for Tin HER2 normal MBC. Proc. Am. Soc. Clin. Oncol. (2004) 22:512a.
   Google Scholar
• PARIDAENS R, BIGANZOLI L, BRUNING P et al.: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. 1 Clin. Oncol. (2000) 18:724–733.
   Google Scholar
• ••Paclitaxel monochemotherapy Phase IIItrials/advanced breast cancer.
   Google Scholar
• SLEDGE GW, NEUBERG D, BERNARDO P et al.: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J. Clin. Oncol. (2003) 21:588–592.
   PubMed Web of Science ®Google Scholar
• ••Paclitaxel monochemotherapy Phase IIItrials/advanced breast cancer.
   Google Scholar
• BISHOP J, DEWAR J, TONER G et al.: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J. Clin. Oncol. (1999) 17:2355–2364.
   PubMed Web of Science ®Google Scholar
• ••Paclitaxel monochemotherapy Phase IIItrials/advanced breast cancer.
   Google Scholar
• SEIDMAN AD, HUDIS C, TIERSTEN A et al.: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J. Clin. Oncol. (1995) 13:2575–2581.
   PubMed Web of Science ®Google Scholar
• FOUNTZILAS G, ATHANASSIADES A. GIANNAKAKIS T et al.: A Phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur. J. Cancer (1996) 32A:47–51.
   Google Scholar
• GIANNI L, MUNZONE E, CAPRI G et al.: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior with anthracyclines. J. Natl. Cancer Inst. (1995) 87:1169–1175.
   PubMed Web of Science ®Google Scholar
• SEIDMAN AD, REICHMAN BS, CROWN JP et al.: Paclitaxel as a second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J. Clin. Oncol. (1995) 15:1152–1159.
   Google Scholar
• MOURIDSEN H, HARVEY V V et al.: Phase III study of docetaxel 100 versus 75 versus 60 mg/m2 as second-line chemotherapy in advanced breast cancer. Breast Cancer Res. Treat. (2002) 81:327a.
   Google Scholar
• TABERNERO J, CLIMENT MA, LLUCH A et al.: A multicentre, randomised Phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann. Oncol. (2004) 15:1358–1365.
   PubMed Web of Science ®Google Scholar
• CHAN S, FRIEDRICHS K, NOEL D et al.: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. (1999) 17(8): 2341–2354.
   PubMed Web of Science ®Google Scholar
• ••Registration trials of docetaxel/advancedbreast cancer.
   Google Scholar
• NABHOLTZ J-M, SENN HJ, BEZWODA WR et al.: Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy./ Clin. Oncol. (1999) 17(5): 1413–1424.
   Google Scholar
• ••Registration trials of docetaxel/advancedbreast cancer.
   Google Scholar
• SJOSTROM J, BLOMQVIST C, MOURIDSEN H et al.: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised Phase III study with crossover on progression by the Scandinavian Breast Group. Eur. J. Cancer. (1999) 35(8):1194–1201.
   PubMed Web of Science ®Google Scholar
• •Docetaxel monochemotherapy Phase III trials/advanced breast cancer.
   Google Scholar
• BONNETERRE J, ROCHE H, MONNIER A et al.: Docetaxel versus 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br. J. Cancer. (2002) 87(11):1210–1215.
   PubMed Web of Science ®Google Scholar
• •Docetaxel monochemotherapy Phase III trials/advanced breast cancer.
   Google Scholar
• RAVDIN P, ERBAN J, OVERMOYER B et al.: Phase III comparison of docetaxel D) and paclitaxel (P) in patients with metastatic breast cancer (MBC).. J. Cancer Suppl (2003) 1:S201. 670a.
   Google Scholar
• •Docetaxel monochemotherapy Phase III trials/advanced breast cancer.
   Google Scholar
• NABHOLTZ JM, REESE DM, MA et al.: Combination chemotherapy for metastatic breast cancer. Exp. Rev Anticancer Ther.(2002) 2:169–180.
   PubMedGoogle Scholar
• •Review taxane-anthracydine combinations/advanced breast cancer.
   Google Scholar
• AMADORI D, FRASSINETI GL, ZOLI Wet al.: A Phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Semin. Oncol (1996) 23 (Suppl. 11):16–22.
   Google Scholar
• HOLMES FA, MADDEN T, RA et al.: Sequence-dependent alteration of doxorubicin pharmacolcinetics by paclitaxel in a Phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. (1996) 14:2713–2721.
   PubMed Web of Science ®Google Scholar
• FISHERMAN JS, COWAN KH, NOONE M et al.: Phase I/II study of 72 hours infusional paclitaxel and doxorubicin with granulocyte colony stimulating factor in patients with metastatic breast cancer. J. Clin. Oncol (1996) 14:774–782.
   PubMed Web of Science ®Google Scholar
• JASSEM J, PIENKOWSKI T, PLUZANSKA A et al.: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphomide as first-line therapy for women with metastatic breast cancer: results of a randomized Phase III multicenter trial. J. Clin. Oncol (2001) 19:1707–1715.
   PubMed Web of Science ®Google Scholar
• ••Paditaxel and anthracydine combinationsPhase III trials/advanced breast cancer.
   Google Scholar
• BIGANZOLI L, CUFER T, P et al.: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter Phase III trial. J. Clin. Oncol (2002) 20:3114–3121.
   PubMed Web of Science ®Google Scholar
• ••Paditaxel and anthracydine combinationsPhase III trials/advanced breast cancer.
   Google Scholar
• LUCK HJ, THOMSSEN C, UNTCH M et al.: Multicentric Phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) versus epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proc. Am. Soc. Clin. Oncol (2000) 19:280a.
   Google Scholar
• •Paditaxel and anthracydine combinations Phase III trials/advanced breast cancer.
   Google Scholar
• CARMICHAEL J: UKCCR trial of and cyclophosphamide (EC) versus epirubicin and Taxol (ET) in the first line treatment of women with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol (2001) 20:22a (Abstract 84).
   Google Scholar
• •Paditaxel and anthracydine combinations Phase III trials/advanced breast cancer.
   Google Scholar
• PAGANI O, SESSA C, NOLE F et al.: Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicenter Phase I-II study. Ann. Oncol (2000) 11:985–991.
   PubMed Web of Science ®Google Scholar
• MAVROUDIS D, ALEXOPOULOS A, ZINAS N et al.: Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter Phase II study. Ann. Oncol (2000) 11:1249–1254.
   PubMedGoogle Scholar
• WENS P, ROCHE H, KERBRAT P et al: Epirubicin-docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.. J. Clin. Oncol (2001) 24:328–335.
   Google Scholar
• NABHOLTZ JM, FALKSON C, CAMPOS D et al.: Docetaxel and doxorubicin (AT) compared to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, Phase III trial. J. Clin. Oncol (2003) 21:968–975.
   PubMed Web of Science ®Google Scholar
• ••Docetaxel and anthracydine combinationsPhase III trials/advanced breast cancer.
   Google Scholar
• NABHOLTZ J, PATERSON A, DIRIX L et al.: A Phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol (2001): 20-22a.
   Google Scholar
• •Docetaxel and anthracydine combinations Phase III trials/advanced breast cancer.
   Google Scholar
• MACKEY JR, PATERSON A, DIRIX LY et al.: Final results of the Phase III trial comparing docetaxel (T),doxorubicin (A) and cyclophosphamide (C) FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol.2002): 21-35a.
   Google Scholar
• •Docetaxel and anthracydine combinations Phase III trials/advanced breast cancer.
   Google Scholar
• BONTENBAL M, BRAUN JJ, CREEMERS GJ et al.: Phase III study comparing AT (adriamycin, docetaxel) to FAC (fluorouracil, adriamycin,) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). Eur. J. Cancer (2003) 1:S201 Docetaxel and anthracydine combinations Phase III trials/advanced breast cancer.
   Google Scholar
• BONNETERRE J, DIERAS V, TUBIANA-HULIN M et al.: Phase II multicentre randomised study of docetaxel plus epirubicin versus 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br. J. Cancer. (2004) 91:1466–1471.
   PubMed Web of Science ®Google Scholar
• •Docetaxel and anthracydine combinations Phase III trials/advanced breast cancer.
   Google Scholar
• SPIELMANN M, TUBIANA-HULIN M, NAMER M et al.: Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised Phase II trial.. J. Cancer. (2002) 86:692–697.
   Google Scholar
• CRESTA S, GRASSELLI G, Met al.: A randomized Phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann. Oncol (2004) 15:433–439.
   Google Scholar
• BRIA E, GIANNARELLI D, FELICI A et al.: Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Cancer (2005) 103:672–679.
   PubMed Web of Science ®Google Scholar
• O'SHAUGHNESSY J, MILES D, VUKELJA S et al.: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J. Clin. Oncol (2002) 20:2812–2823.
   Google Scholar
• ••Docetaxel plus capecitabine Phase III trial/advanced breast cancer.
   Google Scholar
• ALBAIN KS, NAG S,-RUIZ G et al.: Global Phase III study of gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc. Am. Soc. Clin. Oncol (2004) 22:510a.
   Google Scholar
• ••Paditaxel plus gemcitabine Phase III trial/advanced breast cancer.
   Google Scholar
• SLAMON D, GODOLPHIN W, LA et al.: Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707–712.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for breast cancer that overexpresses HER2. N EngL J. Med. (2001) 344:783–792.
   PubMed Web of Science ®Google Scholar
• •• Registration trial of trastuzumab/advanced breast cancer.
   Google Scholar
• EXTRA JM, COGNETTI F, CHAN S et al.: Randomized Phase II trial (M77001) trastuzumab (Trastuzumab) plus106. versus docetaxel alone, as first line in patients with Her-2 positive breast cancer. Eur. J. Cancer2003) I:672a.
   Google Scholar
• PEGRAM MD: Docetaxel and herceptin: for future strategies. Oncologist107.(2001) 6\(Suppl. 3):22–25.
   Google Scholar
• NABHOLTZ J-M, PIENKOWSKI T, NORTHFELT D et al.: Results of two open-label multicentre Phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (cis or) (TCH) as therapy for advanced breast cancer (ABC) in women with tumors-expressing the HER2-neu108.proto-oncogene. Eur. j Cancer (2001) 37\(Suppl. 6):695a.
   Google Scholar
• HURLEY JE, DOLINY P, VELEZ Pet aL: High rate of axillary node clearance with neoadjuvant Herceptin, Taxotere, and cisplatin in locally advanced and breast cancer. Breast Cancer109.Res. Treat. (2001) 69:516a.
   Google Scholar
• YARDLEY DA, GRECO FA, JD et al.: Final results of the Minnie Pearl Cancer Research Network first-line trial of weekly paclitaxel/ carboplatin/herceptin in metastatic breast cancer. Breast Cancer Res. Treat.2002) 76:439a.
   Google Scholar
• ROBERT N, LEYLAND-JONES B, ASMAR Let al.: Phase III comparative of herceptin and paclitaxel with and110.without carboplatin in patients with-2/neu positive advanced breast cancer. Cancer Res. Treat. (2002) 76:35a.111.
   Google Scholar
• •Paditaxel plustrastuzumab plus Phase III trial/advanced breast cancer.
   Google Scholar
• HENDERSON IC, BERRY DA, DEMETRI GD et al.: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.. OncoL (2003) 21:976–983.
   Google Scholar
• ••Registration trial of paclitaxel/early breastcancer.
   Google Scholar
• MAMOUNAS E, BRYANT J, LEMBERSKY B et al.: Paclitaxel (T) doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc. Am. Soc. Clin. OncoL2003) 22:12a.
   Google Scholar
• ALBAIN KS, GREEN SJ, RAVDIN PM et al.: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc. Am. Soc. Clin. Oncol. (2002) 21:143A.
   Google Scholar
• •Paditaxel Phase III trial/early breast cancer. KS, GREEN SJ, RAVDIN PM et al.: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc. Am. Soc. Clin. OncoL (2002) 21:143A. B,
   Google Scholar
• FISHER B,ANDERSON S, WICKERHAM DL et al.: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J. Clin. OncoL (1997) 15:1858–1869.
   Google Scholar
• FISHER B, ANDERSON S, DECILLIS A et al.: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from the national surgical adjuvant breast and bowel project B-25.. Clin. OncoL (1999) 17:3374–3388.
   Google Scholar
• GREEN M, BUZDAR A, SMITH T et al.: Weekly paclitaxel (P) followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3 week (Q3 wk) P therapy followed by FAC - Final results of a prospective Phase III randomized trial. Proc. Am. Soc. Clin. OncoL (2002) 21:135a.
   Google Scholar
• • Paclitaxel randomised trial/neoadjuvant setting.
   Google Scholar
• GASPARINI G: Metronomic scheduling: the future of chemotherapy? Lancet OncoL (2001) 2:733–740.
   PubMedGoogle Scholar
• BUZDAR AU, SINGLETARY SE, VALERO Vet al.: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.. Cancer Res. (2002) 8:1073–1079.
   Google Scholar
• LOESCH D, GRECO FA,'SHAUGNESSY J et al.: A randomized, multicenter Phase III trial comparing regimens of doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer. Breast Cancer Res. Treat. (2004) 88\(suppl 1):28a.
   Google Scholar
• NABHOLTZ J-M, PIENKOWSI T, MACKEY Jet al.: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc. Am. Soc. Clin. OncoL (2002) 21:141a.
   Google Scholar
• •Registration trial of docetaxel/early breast cancer.
   Google Scholar
• MARTIN M, PIENKOWSKI T, MACKEY et al.: TAC improves disease Free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001:55 months follow-up. Breast Cancer Res. Treat. (2003) 82:43a.
   Google Scholar
• •Registration trial of docetaxel/early breast cancer.
   Google Scholar
• ROCHE H, FUMOLEAU P, M et aL: Five Years Analysis of the PACS 01 trial: 6 Cycles of FEC100 versus 3 Cycles of FEC100 Followed by 3 Cycles of Docetaxel (D) for the Adjuvant Treatment of Node Positive Breast Cancer. Breast Cancer Res. Treat. (2004) 83:27a.
   Google Scholar
• •Docetaxel Phase III trial/early breast cancer.
   Google Scholar
• SMITH IC, HEYS SD, HUTCHEON AW et aL: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J. Clin. OncoL (2002) 20:1456–1466.
   PubMed Web of Science ®Google Scholar
• •Docetaxel randomised trial/neoadjuvant setting.
   Google Scholar
• BEAR HD, ANDERSON S, SMITH RE et al.: A randomized trial comparing preoperative (preop) doxorubicin/ cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) Tin patients (pts) with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res. Treat. (2004) 88\(Suppl. 1):26a.
   Google Scholar
• WOLMARK N, WANG J, E et aL: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. NatL Cancer Inst. Monogr. (2001) 30:96–102.
   PubMedGoogle Scholar
• IBRAHIM NK, SAMUELS B, PAGE R et aL: Nanoparticle paclitaxel (ABI- 007) in metastatic breast cancer (MBC): efficacy and evidence of dose-dependent activity in multicenter Phase II studies. Proc. Am. Soc. Clin. Oncol. (2002) 21:209a.
   Google Scholar
• O'SHAUGNESSY J, TJULADIN S, DAVIDSON N et al.: ABI-007 (ABRAXANE114), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy versus Taxol in MBC: a Phase III trial. Breast Cancer Res. Treat. (2004) 88\(Suppl. 1):44a.
   Google Scholar
• BLUM JL, SAWN MA, EDELMAN G et al.: Long term disease control in taxane- metastatic breast cancer treated with nab paclitaxel. Proc. Am. Soc.. Oncol. (2004) 23:543a.
   Google Scholar
• O'SHAUGNESSY JA, BLUM JL, SANDBACH JF et al.: Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. Breast Cancer Res. Treat. (2004) 88\(suppl 1):1070a.
   Google Scholar